S
Steven E. Nissen
Researcher at Cleveland Clinic
Publications - 615
Citations - 68676
Steven E. Nissen is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Intravascular ultrasound & Coronary artery disease. The author has an hindex of 98, co-authored 569 publications receiving 61223 citations. Previous affiliations of Steven E. Nissen include Cairo University & Cleveland Clinic Lerner College of Medicine.
Papers
More filters
Journal ArticleDOI
Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
TL;DR: Compared with placebo or pioglitazone, muraglitazar was associated with an excess incidence of the composite end point of death, major adverse cardiovascular events (MI, stroke, TIA), and CHF, which should not be approved to treat diabetes based on laboratory end points until safety is documented in a dedicated cardiovascular events trial.
Journal ArticleDOI
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
A. Michael Lincoff,Stephen J. Nicholls,Jeffrey S. Riesmeyer,Philip J. Barter,H. Bryan Brewer,Keith A.A. Fox,C. Michael Gibson,Christopher B. Granger,Venu Menon,G. Montalescot,Daniel J. Rader,Alan R. Tall,Ellen McErlean,Kathy Wolski,Giacomo Ruotolo,Burkhard Vangerow,Govinda Weerakkody,Shaun G Goodman,Diego Conde,Darren K. McGuire,Jose C. Nicolau,Jose L. Leiva-Pons,Yves Pesant,Weimin Li,David Kandath,Simon Kouz,Naeem Tahirkheli,Denise Mason,Steven E. Nissen +28 more
TL;DR: Treatment with evacetrapib did not result in a lower rate of cardiovascular events than placebo among patients with high‐risk vascular disease, and had favorable effects on established lipid biomarkers.
Journal ArticleDOI
Risk of cardiovascular events associated with selective COX-2 inhibitors☆
TL;DR: In this article, the authors performed a MEDLINE search to identify all English-language articles on use of COX-2 inhibitors published between1998 and February 2001, which yielded two major randomized trials, the Vioxx Gastrointestinal and the Celecoxib Longterm Arthritis Safety Study (VIGOR), as well as 2 smaller trials with approximately 1000 patients each.
Journal ArticleDOI
Cardiovascular efficacy and safety of bococizumab in high-risk patients
Paul M. Ridker,James H. Revkin,Pierre Amarenco,Robert Brunell,Madelyn Curto,Fernando Civeira,Marcus Flather,Robert J. Glynn,Jean Gregoire,J. Wouter Jukema,Yuri Karpov,John J.P. Kastelein,Wolfgang Koenig,Alberto J. Lorenzatti,Pravin Manga,Urszula Masiukiewicz,Michael Miller,Arend Mosterd,Jan Murin,Jose C. Nicolau,Steven E. Nissen,Piotr Ponikowski,Raul D. Santos,Pamela F. Schwartz,Handrean Soran,Harvey D. White,R. Scott Wright,Michal Vrablík,Carla Yunis,Charles L. Shear,Jean-Claude Tardif +30 more
TL;DR: In two randomized trials comparing the PCSK9 inhibitor bococizumab with placebo, bococzumab had no benefit with respect to major adverse cardiovascular events in the trial involving lower‐risk patients but did have a significant benefit in the Trial involving higher‐risk Patients.
Journal ArticleDOI
Impact of statins on serial coronary calcification during atheroma progression and regression.
Rishi Puri,Stephen J. Nicholls,Mingyuan Shao,Yu Kataoka,Kiyoko Uno,Samir R. Kapadia,E. Murat Tuzcu,Steven E. Nissen +7 more
TL;DR: Independent of their plaque-regressive effects, statins promote coronary atheroma calcification, and these findings provide insight as to how statins may stabilize plaque beyond their effects on plaque regression.